- Citations, last 5 years
- 2 535
- Works, last 5 years
- 111
- h-index
- 103
- Scientists listed
- 0
- Grants since 2016
- 7
Grants received
2024–2027 · research · Diagnostics Accelerator
Validation of a Mass Spectrometry-Based Clinical Lab Workstation and Global Scale-up of Precivity(TM) In-Vitro Diagnostic Testing
Joel Braunstein · C2N Diagnostics (United States) · funded by Alzheimer's Drug Discovery Foundation
2020–2023 · research · Biomarkers
Clinical Validation and Accreditation for Plasma Aß42/Aß40 as a Biomarker for Alzheimer’s Disease Pathology
Kevin Yarasheski · C2N Diagnostics (United States) · funded by Alzheimer's Drug Discovery Foundation
2018 · research · R44
Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis
Tim West · C2N Diagnostics (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis
Tim West · C2N Diagnostics (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis
Tim West · C2N Diagnostics (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Coverage for costs associated with reading of amyloid PET images from PARIS study
Tim West · C2N Diagnostics (United States) · funded by National Institutes of Health
2016–2018 · research · Alzheimer's Disease Research: Other
SILK ABeta SPOT Test
Philip Verghese · C2N Diagnostics (United States) · funded by BrightFocus Foundation